【基本信息】
姓 名： 张秋 
性 别： 女
出生日期：1976.10.28
学 历：博士研究生
学 位：博士
职 称：副教授
电 话：0531-88364681
传 真：0531-88380029
E-mail: zhangqiu@sdu.edu.cn
【教学情况】
《仪器分析实验》、 《无机及分析化学实验》、
《大学化学实验（1）》、 《基础化学实验Ⅴ》
【科研兴趣及方向】
主要从事纳米毒理、抗癌药物的作用机理等化学生物学领域的研究。
【承担研究课题】
1. 国家自然科学基金青年基金：对比羧基化多壁碳纳米管和羧基化石墨烯预暴露对乙型肝炎病毒所致肝损伤的作用研究 (21307077，2014.01-2016.12，负责人)
2. 中国博士后基金面上项目：多壁碳纳米管预暴露对小鼠乙型肝炎的影响及机制研究（2013M541920，2013.09-2015.01，负责人)
3. 教育部博士点基金：羧基化多壁碳纳米管预暴露对乙型肝炎病毒感染所致小鼠肝损伤的影响及机制研究 (20130131120007, 2014.01-2016.12, 负责人)
4. 山东省自然科学基金青年基金：噻唑烷酮类小分子化合物选择性抗脑神经胶质瘤作用的机制研究(ZR2013BQ026, 2013.10-2016.10, 负责人)
5. 教育部留学回国人员启动基金：新型噻唑烷酮化合物选择性抗脑神经胶质瘤作用的实验研究(2014.01-2016.12, 负责人)
6. 山东大学自主创新基金：新型噻唑烷酮类化合物选择性诱导非小细胞肺癌凋亡的机制研究 (2009TS019, 2010.06-2012.12, 负责人)
7. 国家重大基础研究项目（973）子课题: 目标污染物/纳米材料和组装界面的表征方法及污染物去除过程中的安全性评价（2010CB933504, 2010.01-2014.08, 课题骨干）
8. 国家自然科学基金面上项目：纳米颗粒与磷脂分子的相互作用及对磷脂层结构的影响机制 (21377070, 2013.08-2017.12, 第二位）
9. 国家自然科学基金青年基金：基于蛋白酶体为靶点的新型铜配体DiS衍生物库的筛选及其抗癌活性研究（20902054, 2010.01-2012.12, 第二位)
【代表性学术论文】
1. Q Jia, LW Li, QX Mu*, Zhang Q*. Immunomodulation of Nanoparticles in Nanomedicine Applications. Journal of biomedicine and biotechnology. 2014. In press.
2. Li L, Liu Y, Zhang Q, Zhou H, Zhang Y, Yan B*. Comparison of Cancer Cell Survival Triggered by Microtubule Damage after Turning Dyrk1B Kinase On and Off. ACS Chem Biol. 2014;9(3):731-42.
3. Zhang CK, Zhai SM, Li XE, Zhang Q, Wu L, Liu Y, Jiang CJ, Zhou HY, Li F, Zhang SS, Su GX, Zhang B, Yan B*. Synergistic Action by Multi-targeting Compounds Produces a Potent Compound Combination for Human NSCLC both in vitro and in vivo. Cell Death & Disease. Cell Death and Disease.2014,5, e1138.
4. Zhang Q*，Li F. Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles. Curr Pharm Des. 2013;19(37):6655-66.
5. Zhang Q, Liu X, Li X, Li C, Zhou H, Yan B*. Antitumor Activity of (2E,5Z)-5-(2-Hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a Novel Microtubule-Depolymerizing Agent, in U87MG Human Glioblastoma Cells and Corresponding Mouse Xenograft Model. J Pharmacol Sci. 2013;122(3):223-31.
6. Zhang Q, Zhai S, Li L, Li X, Zhou H, Liu A, Su G, Mu Q, Du Y, Yan B*. Anti-tumor selectivity of a novel Tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models. Biochem Pharmacol. 2013; 86(3): 351-60.
7. Sun J, Zhang Q, Wang Z, Yan B*. Effects of nanotoxicity on female reproductivity and fetal development in animal models. Int J Mol Sci. 2013;14(5): 9319-37.
8. Zhang C, Zhang Q, Zhang Y, Yan B*. Toward a Better Understanding of Pharmacokinetics of Nanomaterials. Curr Pharm Des. 2013;19(37):6667-80.
9. Leng X, Zhang Q (co-first author), Zhai X, Chen Z*. Local transplant of human umbilical cord matrix stem cells improves skin flap survival in a mouse model. Tohoku J Exp Med. 2012; 227(3): 191-7.
10. Gao NN, Zhang Q, Mu QX, Bai YH, Li LW, Zhou HY, Butch ER, Powell TB, Snyder SE, Jiang GB, and Yan B*. Steering Carbon Nanotubes to Scavenger Receptor Recognition by Nanotube Surface Chemistry Modification Partially Alleviates NF-κB Activation and Reduces Its Immunotoxicity. ACS Nano. 2011; 5(6), 4581- 91.
11. Li LW, Zhang Q, Liu AF, Li, XE, Zhou HY, Liu Y, Yan B*. Proteome Interrogation Using Nanoprobes to Identify Targets of a Cancer-killing Molecule. J Am Chem Soc. 2011; 133(18), 6886-9.
12. Yu YM, Zhang Q (co-first author), Mu QX, Zhang B, Yan B*. Exploring the Immunotoxicity of Carbon Nanotubes. Nanoscale Res Lett. 2008; 3(8), 271-7.
13. Mu QX, Su GX, Li LW, Gilbertson B, Yu L, Zhang Q, Sun Y-P, Yan B*. Size-Dependent Cell Uptake of Protein-Coated Graphene Oxide Nanosheets. ACS Appl Mater Interfaces. 2012; 4(4), 2259-66.
14. Zhou QF, Dergunov SA, Zhang Y, Li X, Mu QX, Zhang Q, Jiang GB, Pinkhassik F, Yan B*. Safety profile and cellular uptake of biotemplated nanocapsules with nanometer-thin walls. Nanoscale. 2011; 136 (3), 872-7.
15. Zhang Q, Zhou HY, Yan B*. Reducing Nanotube Cytotoxicity Using a Nano-Combinatorial Library Approach. Carbon Nanotubes Methods Mol Biol. 2010; 625:95-107.
16. Zhang Q, Zhou HY, Zhai SM, Yan B*. Natural Product–Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and Their Anticancer Activities. Curr Pharm Des. 2010; 16(16):1826-42.
17. Zhang Q，Feng W, Zhou HY, Zhang B, Yan B*. Advances in Preclinical Small Molecules for the Treatment of Non-Small Cell Lung Cancer. Expert Opin Ther Patents. 2009; 19(6): 731-51.
18. Zhou H, Mu Q, Gao N, Liu A, Xing Y, Gao S, Zhang Q, Qu G, Chen Y, Liu G, Zhang B, Yan B*. A Nano-Combinatorial Library Strategy for the Discovery of Nanotubes with Reduced Protein-Binding, Cytotoxicity, and Immune Response. Nano Letters. 2008; 8(3), 859-65.
19. Liu YG, Liu SX, Liang XH, Zhang Q, Gao LF, Han LH, Cao YL, Hou N, Du J, Sun WS*. Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. Biochem Biophys Res Commun. 2007; 352 (2): 329-34.
20. Liang X, Liu Y(co-first author), Zhang Q, Gao L, Han L, Ma C, Zhang L, Chen YH, Sun W*. Hepatitis B Virus Sensitizes Hepatocytes to TRAIL-Induced Apoptosis through Bax. J Immunol. 2007; 78 (1): 503-10.